Author:
Man Kenny,Eisenstein Neil M.,Hoey David A.,Cox Sophie C.
Abstract
AbstractIn the past decade, extracellular vesicles (EVs) have emerged as key regulators of bone development, homeostasis and repair. EV-based therapies have the potential to circumnavigate key issues hindering the translation of cell-based therapies including functional tissue engraftment, uncontrolled differentiation and immunogenicity issues. Due to EVs’ innate biocompatibility, low immunogenicity, and high physiochemical stability, these naturally-derived nanoparticles have garnered growing interest as potential acellular nanoscale therapeutics for a variety of diseases. Our increasing knowledge of the roles these cell-derived nanoparticles play, has made them an exciting focus in the development of novel pro-regenerative therapies for bone repair. Although these nano-sized vesicles have shown promise, their clinical translation is hindered due to several challenges in the EV supply chain, ultimately impacting therapeutic efficacy and yield. From the biochemical and biophysical stimulation of parental cells to the transition to scalable manufacture or maximising vesicles therapeutic response in vivo, a multitude of techniques have been employed to improve the clinical efficacy of EVs. This review explores state of the art bioengineering strategies to promote the therapeutic utility of vesicles beyond their native capacity, thus maximising the clinical potential of these pro-regenerative nanoscale therapeutics for bone repair.
Graphical Abstract
Funder
Engineering and Physical Sciences Research Council
Science Foundation Ireland
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference226 articles.
1. Loi F, et al. Inflammation, fracture and bone repair. Bone. 2016;86:119–30.
2. Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):61–76.
3. United States Bone and Joint Initiative, The Burden of Musculoskeletal Diseases in the United States (BMUS). Third Edition., 2014. Rosemont, IL, 2014.
4. Calori GM, et al. The use of bone-graft substitutes in large bone defects: any specific needs? Injury-International J Care Injured. 2011;42:S56–S63.
5. Djouad F, et al. Mesenchymal stem cells: New Insights into bone regenerative applications. J Biomaterials Tissue Eng. 2012;2(1):14–28.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献